Crushed venetoclax tablet solution study for blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 39 years old.
- You must have a blood cancer (like leukemia or lymphoma).
- You must already have a central line (like a port or PICC line) for blood draws.
- You must weigh at least 5.5 kg (about 12 pounds).
- You must be prescribed venetoclax as a liquid made from crushed tablets, taken by mouth or through a feeding tube.
- You must agree to use effective birth control during and for six months after the study (if able to become pregnant or father a child).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether venetoclax together with azacitidine can shrink and control advanced blood cancers caused by myeloproliferative neoplasms (MPN) that do not have the BCR-ABL gene. It may help people whose disease has moved into an accelerated or blast phase when standard options haven’t yet included blast-reducing treatment.
This study looks at how the body processes venetoclax when it's given with azacitidine as a first treatment for acute myeloid leukemia (AML). It aims to understand how well the drug works and how the body handles it.
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.